Chinese drug regulators approved APT Medical (SHA:688617) subsidiary Hunan APT Medical Equipment's medical device registration for polyvinyl alcohol embolization microspheres, according to a Wednesday filing with the Shanghai bourse.
The product is used for embolization therapy, or oxygen starvation, of malignant tumors, in solid organs with abundant blood vessels, the filing said.
Shares fell nearly 1% during afternoon trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments